Matthew Ronsheim
Corporate Officer/Principal at ENTASIS THERAPEUTICS HOLDINGS INC.
Net worth: 611 262 $ as of 30/04/2024
Profile
Matthew Ronsheim is currently the Chief Pharmaceutical Sciences Officer at Entasis Therapeutics Holdings, Inc. Prior to this, he was the Executive Director & Head-Chemistry Manufacturing at Enanta Pharmaceuticals, Inc. from 2016 to 2019.
He received his undergraduate degree from Southern Connecticut State University and his doctorate from the University of New Hampshire.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
INNOVIVA, INC.
0.06% | 05/03/2024 | 40,778 ( 0.06% ) | 611 262 $ | 30/04/2024 |
Matthew Ronsheim active positions
| Companies | Position | Start |
|---|---|---|
| ENTASIS THERAPEUTICS HOLDINGS INC. | Corporate Officer/Principal | 01/09/2020 |
Former positions of Matthew Ronsheim
| Companies | Position | End |
|---|---|---|
| ENANTA PHARMACEUTICALS, INC. | Director/Board Member | 01/08/2019 |
Training of Matthew Ronsheim
| Southern Connecticut State University | Undergraduate Degree |
| University of New Hampshire | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| ENANTA PHARMACEUTICALS, INC. | Health Technology |
| Private companies | 1 |
|---|---|
Entasis Therapeutics Holdings, Inc.
 Entasis Therapeutics Holdings, Inc. BiotechnologyHealth Technology Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin. The company was founded in May 2015 and is headquartered in Waltham, MA. | Health Technology |
- Stock Market
- Insiders
- Matthew Ronsheim
